Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

NCT00359086 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
74
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Mirati Therapeutics Inc.